Treatment with rituximab, an anti-CD20 therapy that is used off label for multiple sclerosis (MS), may be associated with a significantly higher risk of developing inflammatory bowel disease (IBD), particularly Crohn’s disease, a large study in Sweden found. After accounting for patient differences, researchers found the risk was…
Rituximab
Recommended Posts
- Study ties MS therapy to higher risk of inflammatory bowel disease
- Review study links physical disability to cognitive problems in MS
- B-cell therapies linked to fewer relapses in early MS, study finds
- Physical activity programs for people with MS show promise, review finds
- Experimental CAR T-cell therapy shows promise in early MS trial